EA200300544A1 - Эффективные противоопухолевые лекарственные средства - Google Patents

Эффективные противоопухолевые лекарственные средства

Info

Publication number
EA200300544A1
EA200300544A1 EA200300544A EA200300544A EA200300544A1 EA 200300544 A1 EA200300544 A1 EA 200300544A1 EA 200300544 A EA200300544 A EA 200300544A EA 200300544 A EA200300544 A EA 200300544A EA 200300544 A1 EA200300544 A1 EA 200300544A1
Authority
EA
Eurasian Patent Office
Prior art keywords
effective anti
tumor medicine
tumor
drug
medicine
Prior art date
Application number
EA200300544A
Other languages
English (en)
Other versions
EA005564B1 (ru
Inventor
Наото Такахаси
Стив Вейтмен
Маурицио Д'Инкальчи
Глинн Томас Фэрклот
Рафаэлла Джавацци
Андреас Гешер
Original Assignee
Фарма Мар, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27399908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200300544(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Фарма Мар, С.А. filed Critical Фарма Мар, С.А.
Publication of EA200300544A1 publication Critical patent/EA200300544A1/ru
Publication of EA005564B1 publication Critical patent/EA005564B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicinal Preparation (AREA)

Abstract

ЕТ-743 применяют для изготовления лекарственного препарата для эффективного лечения опухоли посредством комбинированной терапии, включающей ЕТ-743 и другое лекарственное средство.Отчет о международном поиске был опубликован 2003.04.10.
EA200300544A 2000-11-06 2001-11-06 Эффективные противоопухолевые лекарственные средства EA005564B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24623300P 2000-11-06 2000-11-06
US24809500P 2000-11-13 2000-11-13
US34598201P 2001-10-19 2001-10-19
PCT/GB2001/004902 WO2002036135A2 (en) 2000-11-06 2001-11-06 Compositions for antitumour treatment containing ecteinascidin 743

Publications (2)

Publication Number Publication Date
EA200300544A1 true EA200300544A1 (ru) 2003-08-28
EA005564B1 EA005564B1 (ru) 2005-04-28

Family

ID=27399908

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300544A EA005564B1 (ru) 2000-11-06 2001-11-06 Эффективные противоопухолевые лекарственные средства

Country Status (25)

Country Link
US (3) US20040108086A1 (ru)
EP (1) EP1365808B1 (ru)
JP (2) JP4391083B2 (ru)
KR (1) KR100718946B1 (ru)
CN (1) CN100374162C (ru)
AT (1) ATE495793T1 (ru)
AU (2) AU2002212499B2 (ru)
BG (1) BG107843A (ru)
BR (1) BR0115162A (ru)
CA (1) CA2428160C (ru)
CY (1) CY1112361T1 (ru)
CZ (1) CZ20031327A3 (ru)
DE (1) DE60143911D1 (ru)
DK (1) DK1365808T3 (ru)
EA (1) EA005564B1 (ru)
HK (1) HK1060067A1 (ru)
HU (1) HUP0400648A3 (ru)
IL (1) IL155781A0 (ru)
MX (1) MXPA03003975A (ru)
NO (1) NO329981B1 (ru)
NZ (1) NZ525730A (ru)
PL (1) PL361389A1 (ru)
PT (1) PT1365808E (ru)
SK (1) SK287901B6 (ru)
WO (1) WO2002036135A2 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
DK1365808T3 (da) * 2000-11-06 2011-05-16 Pharma Mar Sa Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
JP2005509650A (ja) * 2001-10-19 2005-04-14 ファルマ・マール・ソシエダード・アノニマ 癌治療における抗腫瘍化合物の改良した使用
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
WO2005049031A1 (en) * 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Combination
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
EP1691809A1 (en) * 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
US20080293725A1 (en) * 2004-07-09 2008-11-27 Rafael Rosell Costa Prognostic Molecular Markers
EP1812114A2 (en) * 2004-09-29 2007-08-01 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti-inflammatory agents
RU2359700C2 (ru) * 2004-10-26 2009-06-27 Фарма Мар С.А., Сосьедад Униперсональ Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
WO2006046079A1 (en) 2004-10-29 2006-05-04 Pharma Mar S.A., Sociedad Unipersonal Formulations comprising ecteinascidin and a disaccharide
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
CA2630900A1 (en) * 2005-11-25 2007-05-31 University Of Medicine And Dentistry Of New Jersey Use of parp-1 inhibitors
US20100267732A1 (en) * 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
CA2995025C (en) * 2010-11-12 2020-04-28 Pharma Mar, S.A. Combination therapy with an antitumor alkaloid
GB201217439D0 (en) * 2012-09-28 2012-11-14 Topotarget As Combination therapy
WO2014165818A2 (en) 2013-04-05 2014-10-09 T Cell Therapeutics, Inc. Compositions and methods for preventing and treating prostate cancer
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
CN109276719A (zh) * 2018-11-01 2019-01-29 中山万汉制药有限公司 含有奥利司他纳米粒与蛋白激酶抑制剂的组合物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
JP4562815B2 (ja) * 1997-05-21 2010-10-13 ジェネンテック, インコーポレイテッド トロンボポエチンの新規な投与
BR9909488B1 (pt) * 1998-04-06 2011-02-08 ecteinascidinas semi-sintéticas e composição farmacêutica.
ES2239442T3 (es) * 1998-05-11 2005-09-16 Pharma Mar, S.A. Metabolitos de ecteinascidina 743.
JP2000081438A (ja) * 1998-06-25 2000-03-21 Sekisui Chem Co Ltd 被験者の癌化学療法による免疫機能低下の測定方法
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) * 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
US7247892B2 (en) * 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
WO2002014554A2 (en) * 2000-08-11 2002-02-21 City Of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
DK1365808T3 (da) * 2000-11-06 2011-05-16 Pharma Mar Sa Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
WO2002076459A1 (en) * 2001-03-06 2002-10-03 Bristol-Myers Squibb Company Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
JP4391038B2 (ja) * 2001-05-10 2009-12-24 パナソニック株式会社 電気炊飯器
JP2005509650A (ja) * 2001-10-19 2005-04-14 ファルマ・マール・ソシエダード・アノニマ 癌治療における抗腫瘍化合物の改良した使用
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
WO2005049031A1 (en) * 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Combination
EP1691809A1 (en) * 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20080293725A1 (en) * 2004-07-09 2008-11-27 Rafael Rosell Costa Prognostic Molecular Markers
EP1812114A2 (en) * 2004-09-29 2007-08-01 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti-inflammatory agents
RU2359700C2 (ru) * 2004-10-26 2009-06-27 Фарма Мар С.А., Сосьедад Униперсональ Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
WO2006046079A1 (en) * 2004-10-29 2006-05-04 Pharma Mar S.A., Sociedad Unipersonal Formulations comprising ecteinascidin and a disaccharide
CA2630900A1 (en) * 2005-11-25 2007-05-31 University Of Medicine And Dentistry Of New Jersey Use of parp-1 inhibitors
WO2007134203A2 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin

Also Published As

Publication number Publication date
JP2009114212A (ja) 2009-05-28
JP4391083B2 (ja) 2009-12-24
CA2428160C (en) 2009-10-13
NZ525730A (en) 2004-12-24
PT1365808E (pt) 2011-04-08
WO2002036135A3 (en) 2003-04-10
EA005564B1 (ru) 2005-04-28
ATE495793T1 (de) 2011-02-15
NO20032027D0 (no) 2003-05-06
EP1365808B1 (en) 2011-01-19
CN100374162C (zh) 2008-03-12
NO20032027L (no) 2003-07-04
CY1112361T1 (el) 2015-12-09
CN1486193A (zh) 2004-03-31
KR100718946B1 (ko) 2007-05-16
US20040108086A1 (en) 2004-06-10
SK287901B6 (sk) 2012-03-02
US20090324744A1 (en) 2009-12-31
EP1365808A2 (en) 2003-12-03
DE60143911D1 (de) 2011-03-03
CZ20031327A3 (cs) 2003-11-12
JP2004517056A (ja) 2004-06-10
KR20030048127A (ko) 2003-06-18
HUP0400648A2 (hu) 2004-06-28
CA2428160A1 (en) 2002-05-10
DK1365808T3 (da) 2011-05-16
AU2002212499B2 (en) 2006-11-02
AU1249902A (en) 2002-05-15
BG107843A (bg) 2004-06-30
HK1060067A1 (en) 2004-07-30
WO2002036135A2 (en) 2002-05-10
SK5492003A3 (en) 2004-03-02
PL361389A1 (en) 2004-10-04
IL155781A0 (en) 2003-12-23
HUP0400648A3 (en) 2012-09-28
NO329981B1 (no) 2011-01-31
US20120107417A1 (en) 2012-05-03
MXPA03003975A (es) 2004-02-12
BR0115162A (pt) 2003-10-21

Similar Documents

Publication Publication Date Title
EA200300544A1 (ru) Эффективные противоопухолевые лекарственные средства
DE50002293D1 (de) Verwendung von csf-1-inhibitoren
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
CY1107054T1 (el) Ενωσεις διτοσυλικου αλατος κιναζολινης
EA200300873A1 (ru) Новая соль сукцинат o-десметилвенлафаксина
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
EA200500859A1 (ru) Хинолинилпирролопиразолы
DE69426334D1 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
CY1114422T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει αρσενικωδες για τη θεραπευτικη αντιμετωπιση κακοηθειας
EA200200742A1 (ru) 1,2-диарилбензимидазолы для лечения заболеваний, связанных с активацией микроглии
ATE174221T1 (de) Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
KR920002151A (ko) 15-케토-프로스타글란딘 화합물에 의한 염증성 질환 치료
ATE456377T1 (de) Behandlung des metastasierenden karzinoms der niere
TR200402230T4 (tr) O-ikameli 6-metil-tramadol-türevleri
ATE223721T1 (de) Edelfosin zur behandlung von hirntumoren
HUP9700661A2 (hu) Alfa1-adrenoreceptor antagonisták felhasználása rák megelőzésére és kezelésére alkalmas gyógyszerkészítmények előállítására
SE0100684D0 (sv) New subject-matter
ES2113345T3 (es) Tratamiento de la disfuncion cardiaca con la ayuda de compuestos 15-ceto-prostaglandina.
SE0004827D0 (sv) Therapeutic compounds
EA200300516A1 (ru) Комбинация, включающая камптотецин и производные стильбена, для лечения рака
EA200401454A1 (ru) Новая комбинация из обратимо действующих ингибиторов протонного насоса и используемых в терапии дыхательных путей лекарственных веществ, предназначенных для лечения респираторных заболеваний
MXPA01007952A (es) Formulaciones a base de l-arginina para tratar enfermedades, y metodos para usarlas.
DK0470144T3 (da) D-Asparaginsyre-beta-hydroxamat til behandling af virale infektioner og tumorer
ES2039436T3 (es) Un procedimiento para preparar una composicion farmaceutica.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU